BC PharmaCare Drug Information

The drug below is being considered for coverage under the BC PharmaCare program. PharmaCare is a government-funded drug plan that helps B.C. residents with the cost of eligible prescription drugs and medical supplies. For more information about PharmaCare, visit the PharmaCare website.

PharmaCare reviews each drug for treating a specific illness or medical condition (also called an "indication"). If PharmaCare decides to cover a drug, that coverage applies only to the indication(s) specified. In some cases, PharmaCare covers a drug only for people who have not responded to other drugs that treat the same indication.

More information about the PharmaCare drug review process is provided on the last page of this document.

Drug information	
Generic name (scientific name)	**plozasiran**
Brand name	**Redemplo™**
Manufacturer	Arrowhead Pharmaceuticals, Inc.
Indication	As an adjunct to diet to reduce triglyceride levels for adult patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS) for whom standard triglyceride lowering therapies have been inadequate.
Has the drug been reviewed by CDA-AMC, or will CDA-AMC be reviewing it? (See note below.)	Yes For more information about the CDA-AMC Reimbursement Review (CRR) of plozasiran (Redemplo™), Search the CDA-AMC Reports.
Public input start date	Wednesday, **April 29**, 2026
Public input closing date	Tuesday, **May 26**, 2026, **at 11:59 pm**
How is the drug taken?	Plozasiran is given by subcutaneous (under the skin) injection.
How often is the drug taken?	Plozasiran is injected once every three months.

Drug information	
General drug and/or drug study information	Familial chylomicronemia syndrome (FCS) is a rare, inherited metabolic disorder in which the body's metabolism does not break down fats consumed through diet or triglycerides properly. Triglycerides are a type of fat found in blood, essential for the body's energy storage. Symptoms of FCS include fatty deposits under the skin, fatigue, gastrointestinal issues like nausea, vomiting, abdominal pain, inflammation of the pancreas (i.e., pancreatitis), as well as other effects on organs like the spleen and liver. Plozasiran works by targeting and changing the genetic material to reduce a specific protein in the body that prevents the breakdown of serum triglycerides. This helps restore the body's ability to break down fats. Studies looked at the following: • Change from baseline in fasting triglyceride levels • Acute pancreatitis attack rate • Health-related quality of life (HRQoL) as measured by the pancreas-specific module of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-PAN26) • Bad reactions • Serious bad reactions • Patients leaving the trial due to bad reactions
Other considerations	None

Note:
CDA-AMC (Canada's Drug Agency-L'Agence des Médicaments du Canada) is a national organization that reviews drugs on behalf of Canadian public sector plans when drug manufacturers want those plans to provide coverage for the drug. For detailed information about the PharmaCare drug review process, including the role of the CDA-AMC Reimbursement Review (CRR) in that process, visit How PharmaCare Decides Which Drugs to Cover.

Table of Comparators Used to Treat the Same Indication		
Generic Name (Brand Name) of Drug Comparator	**Dosage Form**	**PharmaCare Status (if and how the drug is already covered)**
plozasiran (Redemplo™)	Single-use pre-filled syringe for subcutaneous use	Under Review
olezarsen (Tryngolza™)	Pre-filled autoinjector for subcutaneous use	Under Review

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent national organization called Canada's Drug Agency (CDA-AMC) provides evidence-based recommendations to public drug plans across Canada through its reimbursement review process.

As part of the CDA-AMC's Clinical Reimbursement Review process, the Canadian Drug Expert Committee (CDEC) makes reimbursement recommendations for non-oncology pharmaceuticals to the participating federal, provincial, and territorial publicly funded drug plans. In developing its recommendations, the CDEC considers:

- whether the drug is safe and effective
- what the drug costs and whether it is a good value to the citizens of B.C.
- ethical considerations related to covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a BC PharmaCare coverage decision by considering:

- existing BC PharmaCare policies, programs and resources
- the evidence-informed advice of the CDA-AMC
- the recommendations and reimbursement conditions of the CDEC
- if a Ministry Initiated review, the advice of an independent expert group called the Drug Benefit Council (DBC)
- BC-specific patient input collected through the Your Voice website
- drugs already covered by BC PharmaCare that treat similar medical conditions
- the overall cost of covering the drug

Visit BC PharmaCare and Drug reviews for more information.

This document provides information only.
It does not take the place of advice from a physician or other qualified health care provider.